

# Martti Antero FÄörkkilÄö

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2514777/publications.pdf>

Version: 2024-02-01

176  
papers

15,888  
citations

41323

49  
h-index

20943

115  
g-index

186  
all docs

186  
docs citations

186  
times ranked

27086  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	1.9	15
2	Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology, 2022, 75, 59-73.	3.6	15
3	Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. Annals of Surgery, 2022, 276, e79-e85.	2.1	5
4	Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology, 2022, 162, 431-438.e4.	0.6	14
5	Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	1
6	Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. Journal of Hepatology, 2022, 77, 302-311.	1.8	21
7	Immunoassay for trypsinogen-4. Analytical Biochemistry, 2022, , 114681.	1.1	0
8	Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis. Histopathology, 2022, , .	1.6	7
9	Validation of the Chronic Liver Disease (CLivD) score. Journal of Hepatology, 2022, , .	1.8	0
10	Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. Annals of Surgery, 2021, 274, e535-e540.	2.1	12
11	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology, 2021, 19, 1180-1188.e4.	2.4	12
12	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. Journal of Hepatology, 2021, 74, 321-329.	1.8	55
13	Low serum vitamin D level associated with incident advanced liver disease in the general population â€“ a prospective study. Scandinavian Journal of Gastroenterology, 2021, 56, 299-303.	0.6	3
14	Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland. BMJ Open, 2021, 11, e046667.	0.8	25
15	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2021, 12, e00315.	1.3	10
16	Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. PLoS ONE, 2021, 16, e0251392.	1.1	2
17	Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. Diagnostic Pathology, 2021, 16, 41.	0.9	9
18	Presence of interferon-Î» 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology, 2021, 56, 849-854.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Mortality, Reoperation, and Hospital Stay Within 90 Days of Primary and Secondary Antireflux Surgery in a Population-Based Multinational Study. <i>Gastroenterology</i> , 2021, 160, 2283-2290.	0.6	7
20	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2590-2600.	1.9	10
21	Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1020-1027.	0.4	1
22	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , 2021, 161, 1764-1775.e5.	0.6	28
23	Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , 2021, 9, 1128-1135.	1.6	18
24	Hospital Volume of Antireflux Surgery in Relation to Endoscopic and Surgical Re-interventions. <i>Annals of Surgery</i> , 2021, 274, e1138-e1143.	2.1	6
25	Biliary hCG $\beta$ 2 Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. <i>Livers</i> , 2021, 1, 322-329.	0.8	1
26	Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 995-997.e2.	2.4	22
27	Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-up of Population Cohorts. <i>Hepatology</i> , 2020, 71, 835-848.	3.6	96
28	Genetic and lifestyle risk factors for advanced liver disease among men and women. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 291-298.	1.4	16
29	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
30	Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 74-81.	0.6	37
31	Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 384-403.	1.4	33
32	REPLY:. <i>Hepatology</i> , 2020, 71, 1888-1889.	3.6	1
33	Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study. <i>European Journal of Cancer</i> , 2020, 138, 80-88.	1.3	5
34	Evaluating drug targets through human loss-of-function genetic variation. <i>Nature</i> , 2020, 581, 459-464.	13.7	115
35	The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> , 2020, 581, 434-443.	13.7	6,140
36	A structural variation reference for medical and population genetics. <i>Nature</i> , 2020, 581, 444-451.	13.7	614

#	ARTICLE	IF	CITATIONS
37	Transcript expression-aware annotation improves rare variant interpretation. <i>Nature</i> , 2020, 581, 452-458.	13.7	142
38	Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 347-353.	0.6	6
39	Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. <i>United European Gastroenterology Journal</i> , 2020, 8, 462-471.	1.6	7
40	Role of Autoimmunity in Patients Transplanted for Acute Liver Failure of Unknown Origin: A Clinical and Graft Biopsy Analysis. <i>Liver Transplantation</i> , 2020, 26, 764-773.	1.3	3
41	Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. <i>Seminars in Liver Disease</i> , 2020, 40, 154-162.	1.8	41
42	Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 849-854.	0.6	12
43	Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 984-990.	0.6	3
44	LBP-01-In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys. <i>Journal of Hepatology</i> , 2019, 70, e141.	1.8	3
45	THU-251-Metabolic risk factors for advanced liver disease among alcohol risk users in the general population. <i>Journal of Hepatology</i> , 2019, 70, e273.	1.8	5
46	Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 707-711.	0.6	12
47	A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. <i>American Journal of Gastroenterology</i> , 2019, 114, 648-655.	0.2	53
48	Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. <i>Digestive and Liver Disease</i> , 2019, 51, 1294-1299.	0.4	41
49	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1704-1705.	2.0	0
50	Serum lipopolysaccharides predict advanced liver disease in the general population. <i>JHEP Reports</i> , 2019, 1, 345-352.	2.6	27
51	Inflammatory bowel disease and anemia: intravenous iron treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 430-434.	0.6	5
52	Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. <i>Lipids</i> , 2018, 53, 323-334.	0.7	1
53	Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. <i>Hepatology</i> , 2018, 67, 2141-2149.	3.6	178
54	Fecal Calprotectin Test Performed at Home. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 926-931.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
56	<i>Clostridium difficile</i> infection in patients with inflammatory bowel disease: a case control study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 947-951.	0.6	9
57	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2018, 155, 752-759.e5.	0.6	69
58	Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. <i>JAMA Oncology</i> , 2018, 4, 1576.	3.4	16
59	The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. <i>Liver International</i> , 2018, 38, 2329-2339.	1.9	22
60	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , 2018, 14, e1007329.	1.5	66
61	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multicentre study. <i>Liver International</i> , 2017, 37, 1554-1561.	1.9	54
62	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
63	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , 2017, 66, 1214-1222.	1.8	51
64	Histologic surveillance after liver transplantation due to autoimmune hepatitis. <i>Clinical Transplantation</i> , 2017, 31, e12936.	0.8	17
65	<sup>31</sup> Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 886-892.	0.6	7
66	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , 2017, 66, 1265-1281.	1.8	87
67	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , 2017, 49, 588-608.	1.0	154
68	Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis. <i>Liver International</i> , 2017, 37, 735-742.	1.9	13
69	Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
70	Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo). <i>BMJ Open</i> , 2017, 7, e016505.	0.8	14
71	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
72	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230

#	ARTICLE	IF	CITATIONS
73	Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3123-3130.	1.1	30
74	Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1251-1257.	0.8	6
75	Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 321-327.	0.6	10
76	Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 242-249.	0.6	22
77	Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF $\pm$ -blocking agents. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 284-290.	0.6	20
78	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , 2017, 65, 907-919.	3.6	79
79	Biliary Anomalies in Patients With HNF1B Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2075-2082.	1.8	20
80	Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland. <i>Frontiers in Immunology</i> , 2017, 8, 1190.	2.2	49
81	Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. <i>PLoS ONE</i> , 2017, 12, e0182924.	1.1	71
82	Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 6147-6154.	1.4	11
83	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study. <i>PLoS ONE</i> , 2017, 12, e0179764.	1.1	28
84	Environmental Risk Factors of Pediatric Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 437-442.	0.9	15
85	Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996–2013. <i>International Journal of Cancer</i> , 2016, 138, 2616-2621.	2.3	13
86	Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 961-966.	0.6	29
87	A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
88	Outcome of inflammatory bowel disease patients treated with TNF $\pm$ inhibitors: two-year follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1476-1481.	0.6	9
89	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	5.8	50
90	Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 825-832.	1.7	11

#	ARTICLE	IF	CITATIONS
91	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 337-343.	0.6	13
92	Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , 2016, 4, 562-569.	1.6	20
93	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	0.6	114
94	Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. <i>Endoscopy</i> , 2016, 48, 432-439.	1.0	34
95	Infliximab-induced skin manifestations in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 563-571.	0.6	38
96	Does oral $\alpha$ -galactosidase relieve irritable bowel symptoms?. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 16-21.	0.6	13
97	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2016, 11, e0155142.	1.1	10
98	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , 2015, 62, 188-197.	3.6	106
99	Health-related quality of life among patients with primary sclerosing cholangitis. <i>Liver International</i> , 2015, 35, 2194-2201.	1.9	25
100	Malignancies in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 81-89.	0.6	14
101	Helsinki alert of biodiversity and health. <i>Annals of Medicine</i> , 2015, 47, 218-225.	1.5	95
102	A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e93601.	1.1	6
103	Does fecal calprotectin predict short-term relapse after stopping TNF $\alpha$ -blocking agents in inflammatory bowel disease patients in deep remission?. <i>Journal of Crohn's and Colitis</i> , 2014, 9, 33-40.	0.6	80
104	Outcome After Discontinuation of TNF $\alpha$ -blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	0.9	67
105	Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case-control observational study based on registry data. <i>International Journal of Cancer</i> , 2014, 134, 189-196.	2.3	74
106	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. <i>Hepatology</i> , 2014, 59, 2131-2139.	3.6	38
107	Mortality and causes of death in patients with inflammatory bowel disease: A nationwide register study in Finland. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1088-1096.	0.6	59
108	Reply. <i>Hepatology</i> , 2014, 60, 2130-2131.	3.6	0

#	ARTICLE	IF	CITATIONS
109	Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 543-551.	0.6	60
110	Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 42-50.	0.6	27
111	High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e256-e262.	0.6	51
112	Achievement of deep remission during scheduled maintenance therapy with TNF-blocking agents in IBD. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 730-735.	0.6	95
113	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
114	Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 839-847.	0.6	15
115	A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. <i>Endoscopy</i> , 2013, 45, 915-919.	1.0	40
116	Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1405-1413.	0.6	80
117	Dendritic Cells from Crohn's Disease Patients Show Aberrant STAT1 and STAT3 Signaling. <i>PLoS ONE</i> , 2013, 8, e70738.	1.1	18
118	Quality of life following laparoscopic Nissen fundoplication: Assessing short-term and long-term outcomes. <i>World Journal of Gastroenterology</i> , 2013, 19, 3810.	1.4	60
119	In Crohn's Disease, Anti-TNF- $\alpha$ Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-6.	1.5	11
120	Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 528-537.	0.6	139
121	Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 778-784.	0.6	88
122	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. <i>PLoS ONE</i> , 2012, 7, e29370.	1.1	32
123	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1909-1915.	6.3	517
124	Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidy. <i>Liver International</i> , 2012, 32, 783-789.	1.9	30
125	PNPLA 31148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. <i>BMC Medical Genetics</i> , 2012, 13, 82.	2.1	21
126	A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 724-727.	0.6	18



#	ARTICLE	IF	CITATIONS
127	Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF $\alpha$ blocking agents. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2011-2017.	0.9	158
128	Increasing incidence of inflammatory bowel diseases between 2000 and 2007: A nationwide register study in Finland. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 555-561.	0.9	51
129	Impact of Obesity on the Bioavailability of Peginterferon- $\alpha$ 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. <i>PLoS ONE</i> , 2012, 7, e37521.	1.1	19
130	Incidence and Mortality of Peptic Ulcer Disease is Decreasing. <i>Gastroenterology</i> , 2011, 140, S-731.	0.6	0
131	Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 41-47.	0.6	74
132	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	0.6	93
133	Patient-controlled sedation with propofol and remifentanyl for ERCP: a randomized, controlled study. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 260-266.	0.5	50
134	Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial. <i>Gastroenterology</i> , 2011, 140, S-112.	0.6	20
135	Reducing Carcinogenic Acetaldehyde Exposure in the Achlorhydric Stomach With Cysteine. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 516-522.	1.4	18
136	Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 203, 1748-1752.	1.9	45
137	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2011, 53, 1067-1068.	3.6	4
138	Endoscopic monitoring of infliximab therapy in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 947-953.	0.9	31
139	This month in the <i>Scandinavian Journal of Gastroenterology</i> . <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 3-5.	0.6	0
140	Capsule endoscopy in pediatric patients: Technique and results in our first 100 consecutive children. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1138-1143.	0.6	48
141	Esophageal Morbidity and Function in Adults With Repaired Esophageal Atresia With Tracheoesophageal Fistula. <i>Annals of Surgery</i> , 2010, 251, 1167-1173.	2.1	137
142	Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. <i>Quality of Life Research</i> , 2010, 19, 919-928.	1.5	31
143	Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 430-435.	3.6	82
144	Endoscopic evaluation of Crohn's disease activity. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2131-2136.	0.9	130

#	ARTICLE	IF	CITATIONS
145	Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?. <i>Clinical Infectious Diseases</i> , 2010, 50, e22-e25.	2.9	2
146	Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 325-331.	0.6	140
147	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 1198-1206.	0.6	394
148	Societal costs for irritable bowel syndrome – a population based study. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 582-591.	0.6	49
149	PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1562-1569.	0.9	51
150	Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. <i>Quality of Life Research</i> , 2009, 18, 961-969.	1.5	46
151	IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. <i>BMC Medical Genetics</i> , 2009, 10, 8.	2.1	61
152	Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. <i>Liver International</i> , 2009, 29, 153-158.	1.9	8
153	Nizatidine and Gastric Emptying in Functional Dyspepsia. <i>Digestive Diseases and Sciences</i> , 2008, 53, 352-357.	1.1	14
154	Novel CARD15/NOD2 mutations in Finnish patients with Crohn's disease and their relation to phenotypic variation in vitro and in vivo. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 176-185.	0.9	17
155	Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 40-46.	0.9	397
156	Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1118-1124.	0.9	65
157	IL-23/IL-17 immunity as a hallmark of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1175-1184.	0.9	172
158	Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1392-1398.	0.9	206
159	Randomized comparison of 12 or 24 weeks of peginterferon $\alpha$ -2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2008, 47, 1837-1845.	3.6	196
160	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. <i>Hepatology</i> , 2008, 48, 695-695.	3.6	13
161	Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. <i>Liver International</i> , 2008, 28, 787-797.	1.9	23
162	Symptoms, endoscopic findings and histology predicting symptomatic benefit of Helicobacter pylori eradication. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 810-816.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Effect of smoking on gastric histology in <i>Helicobacter pylori</i> -positive gastritis. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1177-1183.	0.6	26
164	Gastroesophageal reflux patients' defective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up. <i>Annals of Medicine</i> , 2008, 40, 74-80.	1.5	5
165	Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 821-830.	0.6	22
166	Comorbidity and use of health-care services among irritable bowel syndrome sufferers. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 799-806.	0.6	48
167	Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1347-1353.	0.6	59
168	Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. <i>Hepatology</i> , 2004, 40, 1379-1386.	3.6	180
169	Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21. <i>European Journal of Human Genetics</i> , 2001, 9, 328-334.	1.4	43
170	Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. <i>European Journal of Haematology</i> , 1996, 56, 82-87.	1.1	62
171	Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: Cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. <i>Hepatology</i> , 1995, 21, 89-95.	3.6	25
172	Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. <i>Hepatology</i> , 1995, 21, 1261-1268.	3.6	23
173	Psychiatric assessment of globus pharyngis patients. <i>Nordic Journal of Psychiatry</i> , 1992, 46, 303-306.	0.7	1
174	Low prevalence of hepatitis C antibodies in chronic liver disease in Finland. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 139-142.	1.5	6
175	Lipid Metabolism in Bile Acid Malabsorption. <i>Annals of Medicine</i> , 1990, 22, 5-13.	1.5	28
176	Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-8.	0.6	0